Clinical Trial Update: A Phase II Study to Evaluate the Efficacy and Safety of MT921 in Subjects With Moderate to Severe Submental Fat [Phase 2]

View source ↗

Summary

Phase II study evaluating MT921 for reduction of submental fat has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Submental Fat

Drugs mentioned

• MT921

Snippet

Sponsor: Medy-Tox | Conditions: Submental Fat | Phase 2 | Status: COMPLETED